Skip to content

A multicenter study of the predictive value of children's modified ROX index in HFNC treatment of acute respiratory failure

A multicenter study of the predictive value of children's modified ROX index in HFNC treatment of acute respiratory failure

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200058677
Enrollment
Unknown
Registered
2022-04-13
Start date
2022-06-01
Completion date
Unknown
Last updated
2024-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute repiratory failure

Interventions

Group of HFNC:Treated with HFNC
Group of intubation:Mechanical ventilation under intubation

Sponsors

Children's Hospital of Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
0.1 Years to 14 Years

Inclusion criteria

Inclusion criteria: 1. Patients who choose to be admitted to the ICU, 28 days =7.3).

Exclusion criteria

Exclusion criteria: 1. Patients who died within 24 hours after being admitted to the ICU; 2. Severe type I respiratory failure, P/F<100mmHg; 3. Children who need immediate tracheal intubation due to suffocation, poisoning, shock, severe nervous system injury, etc., who cannot perform procedural intubation; 4. Children selected for intubation due to diagnostic or therapeutic procedures (bronchoscopy, surgery); 5. Received non-invasive ventilation when HFNC was intolerant; 6. Those with severe nasal obstruction or those who cannot wear HFNC for facial or upper airway surgery; 7. Poor airway protection and high risk of aspiration; 8. Metabolic diseases, autoimmune diseases, immunodeficiency diseases, tumors, and those who have recently received immunosuppressive therapy; 9. Cases with special diseases such as partial organ transplantation, bone marrow dysplasia, human immunodeficiency virus (HIV) infection; 10. Patients with incomplete clinical data, and those whose family members are unwilling to accept the trial in the clinical trial and request to withdraw.

Design outcomes

Primary

MeasureTime frame
Rate of HFNC successful treatment;Survival rate;

Secondary

MeasureTime frame
Arterial blood gas analysis;Liver and kidney function;

Countries

China

Contacts

Public ContactMiao Hongjun

Children's Hospital of Nanjing Medical University

jun848@126.com+86 18951769627

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026